Pulmonary Disease Doctors in Elk Grove Village, IL Accepting Medicare

7 Pulmonary Disease doctors found. Showing 1 - 7

Anurag Mehrotra, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd Ste 510, Elk Grove Village, IL 60007 Phone: 847-981-3660

Jessica Danielle Johnson, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd Ste 510, Elk Grove Village, IL 60007 Phone: 847-981-3660    Fax: 847-956-5108

Dr. Amrik Sivakam Ray, M.D. Internal Medicine - Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 800 Biesterfield Rd Ste 510, Elk Grove Village, IL 60007 Phone: 847-981-3660

Dr. Amit Goyal, M.D. Internal Medicine - Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007 Phone: 847-981-3660

Thomas Murphy, D.O. Internal Medicine - Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007 Phone: 847-981-3660

Sarah Lynn Mann, M.D. Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007 Phone: 847-894-3049

Dr. Rutvik Shah, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Biesterfield Rd Ste 510, Elk Grove Village, IL 60007 Phone: 847-981-3660

News Archive

Salk researchers receive $19.2 million to unravel mysteries of age-related cognitive decline

A team of Salk Institute researchers led by President Rusty Gage has been awarded $19.2 million over eight years by the American Heart Association-Allen Initiative in Brain Health and Cognitive Impairment to investigate mechanisms underlying Alzheimer's disease and aging-related cognitive decline and uncover new therapies.

KYTHERA presents additional data from third ATX-101 Phase II clinical study in submental fat reduction

KYTHERA Biopharmaceuticals, Inc. today presented additional efficacy data from a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under the chin') fat. The expanded analysis focused on additional patient reported outcome measures, including instruments measuring submental fat impact, subject global assessments and subject self-ratings of chin attractiveness.

Babies born to cocaine users fared better when cared for by people who were not their parents

Babies born to cocaine users fared better socially, emotionally and intellectually if they were cared for during their first two years by people who were not their parents, says a new study.

USAID Administrator Shah addresses fight against HIV in children

In this post in the AIDS.gov blog, USAID Administrator Rajiv Shah discusses global efforts to end HIV infections in children. "

Read more Medical News

› Verified 1 days ago